Literature DB >> 1582097

Low-dose DDAVP in nocturnal enuresis.

D W Key1, D A Bloom, J Sanvordenker.   

Abstract

A five-year experience with the vasopressin analogue desmopressin acetate (DDAVP) for nocturnal enuresis is described in 59 children. The initial starting dose of 5 micrograms at bedtime is lower than that reported in other series. Eighty-one percent of patients required 10 micrograms or less to achieve improvement or resolution of bedwetting.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582097     DOI: 10.1177/000992289203100507

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  5 in total

1.  [Profile of biostatistics utilization in three medical reviews. Implications for medical education].

Authors:  R J Gagnon; R Marchand; M Marcil
Journal:  Can Fam Physician       Date:  1996-05       Impact factor: 3.275

Review 2.  Hyponatremia in patients with nocturnal enuresis treated with DDAVP.

Authors:  W L Robson; J P Nørgaard; A K Leung
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

Review 3.  Side effects and complications of treatment with desmopressin for enuresis.

Authors:  W L Robson; A K Leung
Journal:  J Natl Med Assoc       Date:  1994-10       Impact factor: 1.798

Review 4.  Drug therapy for nocturnal enuresis. Current treatment recommendations.

Authors:  K Miller; B Atkin; M L Moody
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 5.  Nocturnal enuresis.

Authors:  U S Alon
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.